Head and Neck Squamous Cell Carcinomas (HNSCC) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Head And Neck Squamous Cell Carcinomas Market Report Overview
The Head and Neck Squamous Cell Carcinomas (HNSCC) market size for the 15 markets (15M) was $1.9 billion in 2021. HNSCC have an active cell therapy pipeline and one of the largest gene therapy/oncolytic virus clinical pipelines across all oncology indications. HNSCCs are characteristically aggressive tumors, disseminating relatively early, as observed in the high rates of metastatic disease at diagnosis. Late-stage cases constitute around 60% of all HNSCC cases. The growth of the primary tumor is associated with the presence of immune cells, which cause the inflammation frequently observed in HNSCC.
The Head and Neck Squamous Cell Carcinomas market research report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for HNSCC.
Market Size (2021 in 15M) | $1.9 billion |
Key Regions | APAC, Europe, the Middle East, and North America |
Leading Players | SQZ Biotechnologies Co, MeiraGTx Holdings Plc, Fate Therapeutics Inc, Adaptimmune Therapeutics Plc, Zhejiang Yangshengtang Biotech Co., Wuhan Binhui Biotechnology Co Ltd, Turnstone Biologics Inc, and Replimune Ltd |
Head and Neck Squamous Cell Carcinomas Market Dynamics
The key factors influencing the HNSCC market growth positively are established immune checkpoint inhibitors having a high ACOT and sales in the 8MM. HNSCC has one of the largest gene therapy and oncolytic virus pipelines, with one oncolytic virus, RP-2, being anticipated to launch over the forecast period at a lucrative price.
However, current marketed gene therapies, Gendicine and Oncorine, are not expected to have any label expansions or to launch in any other market during the forecast period. The market for gene therapies, especially those using viral vectors, is expected to be slowed down by the high cost of the therapies, which may limit their accessibility.
For more Head and Neck Squamous Cell Carcinomas market insights, download a free report sample
Head and Neck Squamous Cell Carcinomas Market Segmentation by Regions
The key regions in the HNSCC market are APAC, Europe, the Middle East, and North America. APAC had the highest share in 2021. The 15 markets comprise the 8MM and seven countries known to have increased potential for cell and gene therapies given the current drug development landscape, namely Australia, Belgium, Canada, Denmark, Israel, South Korea, and Switzerland.
HNSCC Market Analysis by Regions, 2021 (%)
For more regional insights on the HNSCC market, download a free report sample
Head and Neck Squamous Cell Carcinomas Market - Competitive Landscape
Some of the leading players in the HNSCC market are SQZ Biotechnologies Co, MeiraGTx Holdings Plc, Fate Therapeutics Inc, Adaptimmune Therapeutics Plc, Zhejiang Yangshengtang Biotech Co., Wuhan Binhui Biotechnology Co Ltd, Turnstone Biologics Inc, and Replimune Ltd among others. The clinical pipeline for CGTs in HNSCC is dispersed over many different companies, largely consisting of small medium sized US or China based biotechs.
Some established names such as Replimune, which is a well-known company in the oncolytic virus field, have trials that are sponsored by Bristol Myers Squibb. There is an even mix of ongoing clinical trials investigating cell therapies and gene therapies, as well as upcoming events that include both molecule types in HNSCC. Unlike in hematological malignancies, approvals based on Phase II data are highly unlikely in HNSCC therefore the future players will be better elucidated when Phase III trials have been initiated.
To know more about leading HNSCC market players, download a free report sample
Scope
This report provides an in-depth analysis of the following:
- Overview of HNSCC including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline HNSCC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HNSCC therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).
- Analysis of the current and future market competition in the global HNSCC therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a PowerPoint report and Excel-based forecast model
Forecast includes 8 countries
Forecast covers 2021-2031
Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics
Reasons to Buy
- Obtain cell & gene therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
- Our indication-specific forecast models answer questions such as:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Table of Contents
Frequently asked questions
-
What was the HNSCC market size in the 15M in 2021?
The HNSCC market size for the 15 markets (15M) was $1.9 billion in 2021.
-
Which are the key regions in the HNSCC market?
The key regions in the HNSCC market are APAC, Europe, the Middle East, and North America.
-
Which region had the highest share in the HNSCC market in 2021?
APAC had the highest share of the HNSCC market in 2021.
-
Who are the leading players in the HNSCC market?
Some of the leading players in the HNSCC market are SQZ Biotechnologies Co, MeiraGTx Holdings Plc, Fate Therapeutics Inc, Adaptimmune Therapeutics Plc, Zhejiang Yangshengtang Biotech Co., Wuhan Binhui Biotechnology Co Ltd, Turnstone Biologics Inc, and Replimune Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.